Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.75 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 10/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | TSHR | P16473 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.63 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | STAT1 | P42224 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24654650 | 0.86 | L3MBTL1 (0.78) | L3MBTL1PTK2RAB9ASMN1; SMN2TSHR | |
| SCHEMBL614739 | 0.85 | L3MBTL1 (0.70) | L3MBTL1PTK2RAB9ASMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL329950 | 0.83 | L3MBTL1 (0.68) | L3MBTL1PTK2RAB9ASMN1; SMN2TSHR | |
| Lithium SCHEMBL209869 | 0.83 | L3MBTL1 (0.68) | L3MBTL1PTK2RAB9ASMN1; SMN2TSHR | |
| SCHEMBL209867 | 0.83 | L3MBTL1 (0.68) | L3MBTL1PTK2RAB9ASMN1; SMN2TSHR | |
| SCHEMBL16295141 | 0.83 | MAPT (0.69) | L3MBTL1PTK2RAB9ASMN1; SMN2TSHR | |
| SCHEMBL1431137 | 0.82 | PTK2 (1.00) | L3MBTL1PTK2RAB9ASMN1; SMN2TSHR | |
| SCHEMBL5032454 | 0.82 | L3MBTL1 (0.72) | L3MBTL1PTK2RAB9ASMN1; SMN2TSHR | |
| SCHEMBL26274442 | 0.82 | L3MBTL1 (0.72) | L3MBTL1PTK2RAB9ASMN1; SMN2TSHR | |
| SCHEMBL27886037 | 0.82 | TDP1 (0.73) | L3MBTL1PTK2RAB9ASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2909170-A1 | SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-08-26 | — | — | EP | claimed |
| US-20150218141-A1 | SUBSTITUTED CARBAMATE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | claimed |
| WO-2014060341-A1 | SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-24 | — | — | WO | claimed |
| CN-114591212-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-4019022-B1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2024-01-31 | — | — | EP | disclosed |
| US-11807605-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4019022-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3355890-B1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11066360-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021127459-A1 | GPR139 RECEPTOR MODULATORS | BLACKTHORN THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20200361867-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2020-11-19 | — | — | US | disclosed |
| WO-2014060341-A1 | SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-24 | — | — | WO | disclosed |
| WO-2013163466-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-0033231-B1 | INSECTICIDAL COMPOSITIONS CONTAINING 2,6-DIHALOBENZOYLUREA DERIVATIVES | ELI LILLY AND COMPANY (US) | 1984-06-13 | — | — | EP | disclosed |
| US-4338321-A | FOR INCLUSION IN CATTLE OR POULTRY FEEDS | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| EP-0033231-A1 | Insecticidal compositions containing 2,6-dihalobenzoylurea derivatives | ELI LILLY AND COMPANY (US) | 1981-08-05 | — | — | EP | disclosed |
| US-4281003-A | 1-(2-6-Dihalobenzoyl)-3-(5-substituted-2-pyridinyl)urea insecticides and insecticidal method | ELI LILLY AND COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| US-3969362-A | FUNGICIDE | ISHIHARA SANGYO KAISHA LTD. (JA) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066360-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | L3MBTL1 3331/4885PTK2 1287/4885RAB9A 2232/4885 |
| US-20150218141-A1 | SUBSTITUTED CARBAMATE COMPOUNDS | TRPA1, TRPV1, TRPV3 | L3MBTL1 3512/4885PTK2 4388/4885RAB9A 2411/4885 |
| US-11807605-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | L3MBTL1 3331/4885PTK2 1287/4885RAB9A 2232/4885 |
| US-20200361867-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | L3MBTL1 3331/4885PTK2 1287/4885RAB9A 2232/4885 |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | L3MBTL1 661/4885PTK2 4791/4885RAB9A 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.